SARCOMA/PDGFRα
The targeting of activated fibroblasts in the tumour micro-environment is a promising strategy to elucidate durable treatment responses in certain solid tumors. Telix’s TLX300 program consists of antibody-directed targeted radiation for both diagnostic and therapeutic applications, against platelet-derived growth factor receptor alpha, or PDGFRα. This program originated as an in-licensing arrangement from Eli Lilly & Company, involving the re-purposing of a naked antibody drug (formerly marketed at LARTRUVO®) into a highly promising radiopharmaceutical asset.
Imaging: TLX300-CDx in STS (Phase I, start-up)
